Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
The US Food and Drug Administration has approved a new, nonopioid pain medication for treating moderate to severe acute pain.
Journavx is designed to eliminate the risks of addiction and overdose associated with medications like Vicodin and OxyContin.
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...
U.S.-based Vertex Pharmaceuticals (VRTX) has secured approval from the FDA (Food and Drug Administration) for its ...
The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...
Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Suzetrigine prevents pain signals from reaching the brain and doesn't give an opioid-like high, making it non-addictive—but ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...